{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:56:56Z","timestamp":1781891816645,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,19]]},"DOI":"10.7759\/cureus.111160","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:40:09Z","timestamp":1781890809000},"source":"Crossref","is-referenced-by-count":0,"title":["Short- Versus Standard-Duration Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Mohammad","family":"Khalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahia","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15072472","article-title":"Redefining dual antiplatelet strategies after acute coronary syndrome: insights from recent RCTs","volume":"15","author":"He M","year":"2026","unstructured":"He M, Magdy J, Aziz M, Tan J, Das A, Wheatcroft SB, Bulluck H. Redefining dual antiplatelet strategies after acute coronary syndrome: insights from recent RCTs. J Clin Med. 2026, 15:2472. 10.3390\/jcm15072472","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne RA","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al.. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023, 44:3720-826. 10.1093\/eurheartj\/ehad191","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001309","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"151","author":"Rao SV","year":"2025","unstructured":"Rao SV, O'Donoghue ML, Ruel M, et al.. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2025, 151:e771-862. 10.1161\/CIR.0000000000001309","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri L","year":"2014","unstructured":"Mauri L, Kereiakes DJ, Yeh RW, et al.. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014, 371:2155-66. 10.1056\/NEJMoa1409312","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp110","article-title":"Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial","volume":"30","author":"Mehran R","year":"2009","unstructured":"Mehran R, Pocock SJ, Stone GW, et al.. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009, 30:1457-66. 10.1093\/eurheartj\/ehp110","journal-title":"Eur Heart J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-021-00598-1","article-title":"Bleeding avoidance strategies in percutaneous coronary intervention","volume":"19","author":"Capodanno D","year":"2022","unstructured":"Capodanno D, Bhatt DL, Gibson CM, et al.. Bleeding avoidance strategies in percutaneous coronary intervention. Nat Rev Cardiol. 2022, 19:117-32. 10.1038\/s41569-021-00598-1","journal-title":"Nat Rev Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial","volume":"403","author":"Ge Z","year":"2024","unstructured":"Ge Z, Kan J, Gao X, et al.. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Lancet. 2024, 403:1866-78. 10.1016\/S0140-6736(24)00473-2","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial","volume":"149","author":"Hong SJ","year":"2024","unstructured":"Hong SJ, Lee SJ, Suh Y, et al.. Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial. Circulation. 2024, 149:562-73. 10.1161\/CIRCULATIONAHA.123.066943","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran R","year":"2019","unstructured":"Mehran R, Baber U, Sharma SK, et al.. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019, 381:2032-42. 10.1056\/NEJMoa1908419","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)","volume":"15","author":"De Luca G","year":"2019","unstructured":"De Luca G, Damen SA, Camaro C, et al.. Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). EuroIntervention. 2019, 15:e990-8. 10.4244\/EIJ-D-19-00539","journal-title":"EuroIntervention"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe H","year":"2022","unstructured":"Watanabe H, Morimoto T, Natsuaki M, et al.. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiol. 2022, 7:407-17. 10.1001\/jamacardio.2021.5244","journal-title":"JAMA Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn JY","year":"2018","unstructured":"Hahn JY, Song YB, Oh JH, et al.. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018, 391:1274-84. 10.1016\/S0140-6736(18)30493-8","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.61336\/ejcm\/25-09-116","article-title":"Abbreviated versus standard dual antiplatelet therapy after drug-eluting stent implantation: an updated meta-analysis","volume":"15","author":"Mathur A","year":"2025","unstructured":"Mathur A, Sharma A. Abbreviated versus standard dual antiplatelet therapy after drug-eluting stent implantation: an updated meta-analysis. Eur J Cardiovasc Med. 2025, 15:710-20. 10.61336\/ejcm\/25-09-116","journal-title":"Eur J Cardiovasc Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa670","article-title":"Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS","volume":"41","author":"Baber U","year":"2020","unstructured":"Baber U, Dangas G, Angiolillo DJ, et al.. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J. 2020, 41:3533-45. 10.1093\/eurheartj\/ehaa670","journal-title":"Eur Heart J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim BK","year":"2020","unstructured":"Kim BK, Hong SJ, Cho YH, et al.. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020, 323:2407-16. 10.1001\/jama.2020.7580","journal-title":"JAMA"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli M","year":"2021","unstructured":"Valgimigli M, Frigoli E, Heg D, et al.. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021, 385:1643-55. 10.1056\/NEJMoa2108749","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the  SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn JY","year":"2019","unstructured":"Hahn JY, Song YB, Oh JH, et al.. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the  SMART-CHOICE randomized clinical trial. JAMA. 2019, 321:2428-37. 10.1001\/jama.2019.8146","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf784.3126","article-title":"A shorter duration of dual-antiplatelet therapy following percutaneous coronary intervention: a meta-analysis of randomized clinical trials","volume":"46","author":"Fretz T","year":"2025","unstructured":"Fretz T, Dasari S, Alam Kayani A, et al.. A shorter duration of dual-antiplatelet therapy following percutaneous coronary intervention: a meta-analysis of randomized clinical trials. Eur Heart J. 2025, 46:ehaf784.3126. 10.1093\/eurheartj\/ehaf784.3126","journal-title":"Eur Heart J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega JL","year":"2009","unstructured":"Mega JL, Close SL, Wiviott SD, et al.. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009, 360:354-62. 10.1056\/NEJMoa0809171","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin L","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al.. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009, 361:1045-57. 10.1056\/NEJMoa0904327","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y(12) inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"Gragnano F","year":"2023","unstructured":"Gragnano F, Cao D, Pirondini L, et al.. P2Y(12) inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol. 2023, 82:89-105. 10.1016\/j.jacc.2023.04.051","journal-title":"J Am Coll Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial","volume":"396","author":"Kim HS","year":"2020","unstructured":"Kim HS, Kang J, Hwang D, et al.. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet. 2020, 396:1079-89. 10.1016\/S0140-6736(20)31791-8","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim CJ","year":"2021","unstructured":"Kim CJ, Park MW, Kim MC, et al.. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021, 398:1305-16. 10.1016\/S0140-6736(21)01445-8","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI","volume":"381","author":"Claassens DM","year":"2019","unstructured":"Claassens DM, Vos GJ, Bergmeijer TO, et al.. A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI. N Engl J Med. 2019, 381:1621-31. 10.1056\/NEJMoa1907096","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-022-02476-1","article-title":"De-escalation of antiplatelet therapy after percutaneous coronary intervention among East Asians and non-East Asians: a meta-analysis of randomized controlled trials","volume":"22","author":"Wang G","year":"2022","unstructured":"Wang G, Wang X, Zhao G, Huang X, Guo R, Nie S. De-escalation of antiplatelet therapy after percutaneous coronary intervention among East Asians and non-East Asians: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2022, 22:29. 10.1186\/s12872-022-02476-1","journal-title":"BMC Cardiovasc Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/488583-short--versus-standard-duration-dual-antiplatelet-therapy-after-percutaneous-coronary-intervention-in-acute-coronary-syndrome-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:40:10Z","timestamp":1781890810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/488583-short--versus-standard-duration-dual-antiplatelet-therapy-after-percutaneous-coronary-intervention-in-acute-coronary-syndrome-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.111160","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,19]]}}}